Narcolepsy Clinical Trial
— NARCOWORKOfficial title:
Evaluation of Academic and Professional Trajectories of Narcoleptic Patients
NCT number | NCT03173378 |
Other study ID # | 69HCL17_0252 |
Secondary ID | |
Status | Completed |
Phase | |
First received | |
Last updated | |
Start date | October 3, 2017 |
Est. completion date | July 10, 2018 |
Verified date | November 2018 |
Source | Hospices Civils de Lyon |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
Narcolepsy is a chronic, disabling condition characterized by excessive daytime sleepiness
and, in some patients, falls in muscle tone related to emotions (cataplexies). It often
begins in childhood or in young adults. Symptoms of narcolepsy are responsible for an
important handicap in everyday life, and are often misunderstood by the family and
professional environment. In addition, many comorbidities are associated with narcolepsy,
such as depression, anxiety, or obesity.
Few studies have examined the impact of narcolepsy on patients' educational background,
socio-professional integration, and quality of life. In particular, the factors of
professional handicap related to the characteristics of the disease and the determinants of
the insertion of the patients remain poorly known.
As a better understanding of these determinants could help to inform patients and guide them
in their choices, NARCOWORK study aims at evaluating the academic and professional
trajectories of a wide population of narcoleptic patients.
Status | Completed |
Enrollment | 149 |
Est. completion date | July 10, 2018 |
Est. primary completion date | July 10, 2018 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: Group "Narcoleptic Patients": - Type 1 or Type 2 narcolepsy - > 18 years - Usually followed at the Lyon Sleep Medicine Center Group "Control": - At least one member of each family of cases (siblings, cousins ...) - > 18 years and of the same age as the case if possible (+/- 5 years) - No narcolepsy Exclusion Criteria: - uncertain diagnosis (for the "Narcoleptic Patients" Group) - poor knowledge of the French language - Refusal to participate |
Country | Name | City | State |
---|---|---|---|
France | Sleep Medicine Center, Croix-Rousse Hospital, Hospices Civils de Lyon | Lyon |
Lead Sponsor | Collaborator |
---|---|
Hospices Civils de Lyon |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Occupational situations | Participants will have to complete questionnaires to compare the distribution of occupational situations subjects (worker, unemployed, student, retired, housewife) in narcoleptic patients and matched non-narcoleptic subjects (controls) | 30 to 45 minutes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04072380 -
A Study to Evaluate Safety, and Efficacy of SUVN-G3031 (Samelisant) in Patients With Narcolepsy With and Without Cataplexy
|
Phase 2 | |
Withdrawn |
NCT03626727 -
Evaluation of the Efficacy of Sodium Oxybate (Xyrem®) in Treatment of Post-traumatic Narcolepsy and Post-traumatic Hypersomnia
|
Early Phase 1 | |
Completed |
NCT02821715 -
Safety and Efficacy of THN102 on Sleepiness in Narcoleptic Patients
|
Phase 2 | |
Completed |
NCT01681121 -
A Study of the Safety and Effectiveness of ADX-N05 for Excessive Daytime Sleepiness in Subjects With Narcolepsy
|
Phase 2 | |
Completed |
NCT01789398 -
Patient Narcoleptic Treated With BF2.649 (Pitolisant) in add-on to Sodium Oxybate (HARMONY IV)
|
Phase 3 | |
Completed |
NCT00174174 -
Provigil (Modafinil) Study by Taiwan Biotech Co.
|
N/A | |
Completed |
NCT05059223 -
A Study to Assess the Efficacy and Safety of AXS-12 (Reboxetine) in Patients With Narcolepsy
|
Phase 3 | |
Completed |
NCT04923594 -
Four-week Study of the Safety and Efficacy of NLS-2 (Mazindol Extended Release) in the Treatment of Narcolepsy
|
Phase 2 | |
Recruiting |
NCT06279247 -
Proteomics and Metabolomics of Body Fluid in Patients With Narcolepsy
|
||
Completed |
NCT04647903 -
Study to Evaluate the Abuse Liability, Pharmacokinetics, Safety and Tolerability of an Abuse-Deterrent d-Amphetamine Sulfate Immediate Release Formulation (ADAIR)
|
Phase 1 | |
Completed |
NCT03267303 -
A Study to Evaluate the Safety and Efficacy of TS-091 in Patients With Narcolepsy
|
Phase 2 | |
Completed |
NCT05055024 -
An Open Label Study of NLS-2 (Mazindol Extended Release) in Subjects With Narcolepsy
|
Phase 2 | |
Completed |
NCT01067235 -
Efficacy and Safety Study of BF2.649 and BF2.649 Add on Modafinil on Cataplexy in Patients With Narcolespy
|
Phase 3 | |
Completed |
NCT00228566 -
Study to Assess Patient Reported Outcomes With Armodafinil Treatment for Excessive Sleepiness in Adults With Narcolepsy or Obstructive Sleep Apnea/Hypopnea Syndrome
|
Phase 3 | |
Completed |
NCT00107796 -
Study of PROVIGIL ® (Modafinil) Treatment in Children and Adolescents With Excessive Sleepiness Associated With Narcolepsy
|
Phase 3 | |
Completed |
NCT00132873 -
Trial of Xyrem® (Sodium Oxybate) for the Treatment of Narcolepsy
|
Phase 3 | |
Completed |
NCT00107848 -
PROVIGIL® (Modafinil) Treatment in Children and Adolescents With Excessive Sleepiness Associated With Narcolepsy or Obstructive Sleep Apnea/Hypopnea Syndrome
|
Phase 3 | |
Enrolling by invitation |
NCT05113745 -
A Study to Assess the Long-term Efficacy and Safety of AXS-12 (Reboxetine) in Subjects With Narcolepsy
|
Phase 3 | |
Suspended |
NCT04419792 -
'A Profile of Physical Performance Variables in an Out-patient Adult Population With Narcolepsy'
|
||
Recruiting |
NCT04899947 -
Child and Adolescent Registry for Participants With Narcolepsy
|